These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34597873)

  • 1. Drug resistance mutations in HIV: new bioinformatics approaches and challenges.
    Blassel L; Zhukova A; Villabona-Arenas CJ; Atkins KE; Hué S; Gascuel O
    Curr Opin Virol; 2021 Dec; 51():56-64. PubMed ID: 34597873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Phylogenetics as a Tool to Predict the Spread of Resistance.
    Zhukova A; Cutino-Moguel T; Gascuel O; Pillay D
    J Infect Dis; 2017 Dec; 216(suppl_9):S820-S823. PubMed ID: 29029155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.
    Chaillon A; Nakazawa M; Wertheim JO; Little SJ; Smith DM; Mehta SR; Gianella S
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.
    Karchava M; Pulver W; Smith L; Philpott S; Sullivan TJ; Wethers J; Parker MM
    J Acquir Immune Defic Syndr; 2006 Aug; 42(5):614-9. PubMed ID: 16868498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep sequencing of HIV: clinical and research applications.
    Chabria SB; Gupta S; Kozal MJ
    Annu Rev Genomics Hum Genet; 2014; 15():295-325. PubMed ID: 24821496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standing genetic variation and the evolution of drug resistance in HIV.
    Pennings PS
    PLoS Comput Biol; 2012; 8(6):e1002527. PubMed ID: 22685388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults.
    Hamilton CL; Eyzaguirre LM; Amarakoon II; Figueroa P; Duncan J; Carr JK; Roye ME
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):923-7. PubMed ID: 22049946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmitted HIV drug resistance and subtype patterns among blood donors in Poland.
    Parczewski M; Sulkowska E; Urbańska A; Scheibe K; Serwin K; Grabarczyk P
    Sci Rep; 2021 Jun; 11(1):12734. PubMed ID: 34140600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
    Johnson JA; Li JF; Wei X; Lipscomb J; Irlbeck D; Craig C; Smith A; Bennett DE; Monsour M; Sandstrom P; Lanier ER; Heneine W
    PLoS Med; 2008 Jul; 5(7):e158. PubMed ID: 18666824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
    Dalmat RR; Makhsous N; Pepper GG; Magaret A; Jerome KR; Wald A; Greninger AL
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30305383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Martinson NA; Morris L; Gray G; Moodley D; Pillay V; Cohen S; Dhlamini P; Puren A; Bhayroo S; Steyn J; McIntyre JA
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):148-53. PubMed ID: 17117145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype.
    Parczewski M; Leszczyszyn-Pynka M; Witak-Jędra M; Maciejewska K; Rymer W; Szymczak A; Szetela B; Gąsiorowski J; Bociąga-Jasik M; Skwara P; Garlicki A; Grzeszczuk A; Rogalska M; Jankowska M; Lemańska M; Hlebowicz M; Barałkiewicz G; Mozer-Lisewska I; Mazurek R; Lojewski W; Grąbczewska E; Olczak A; Jabłonowska E; Clark J; Urbańska A
    J Antimicrob Chemother; 2015 Jan; 70(1):233-42. PubMed ID: 25248322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.
    Kühnert D; Kouyos R; Shirreff G; Pečerska J; Scherrer AU; Böni J; Yerly S; Klimkait T; Aubert V; Günthard HF; Stadler T; Bonhoeffer S;
    PLoS Pathog; 2018 Feb; 14(2):e1006895. PubMed ID: 29462208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.
    Su B; Zheng X; Liu Y; Liu L; Xin R; Lu H; Huang C; Bai L; Mammano F; Zhang T; Wu H; Sun L; Dai L
    J Antimicrob Chemother; 2019 May; 74(5):1408-1416. PubMed ID: 30668734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
    Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
    J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Levels of Transmitted HIV Drug Resistance in a Study in Papua New Guinea.
    Lavu E; Kave E; Mosoro E; Markby J; Aleksic E; Gare J; Elsum IA; Nano G; Kaima P; Dala N; Gurung A; Bertagnolio S; Crowe SM; Myatt M; Hearps AC; Jordan MR
    PLoS One; 2017; 12(2):e0170265. PubMed ID: 28146591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
    Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
    Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
    Stekler JD; Milne R; Payant R; Beck I; Herbeck J; Maust B; Deng W; Tapia K; Holte S; Maenza J; Stevens CE; Mullins JI; Collier AC; Frenkel LM
    PLoS Med; 2018 Mar; 15(3):e1002537. PubMed ID: 29584723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania.
    Mosha F; Urassa W; Aboud S; Lyamuya E; Sandstrom E; Bredell H; Williamson C
    AIDS Res Hum Retroviruses; 2011 Apr; 27(4):377-82. PubMed ID: 20954839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.